Lakefront Biotherapeutics (LKFT) Cash & Equivalents (2013 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Cash & Equivalents for 13 consecutive years, with $78.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 97.75% year-over-year to $78.2 million; the TTM figure through Mar 2026 stood at $78.2 million (down 97.75% YoY), while the FY2025 annual figure was $102.3 million, down 97.12% from the prior year.
• Cash & Equivalents fell to $78.2 million in Q1 2026 per LKFT's latest filing, from $102.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $3.9 billion in Q1 2024 and bottomed at $68.6 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $1.7 billion across 5 years, with a median of $963.1 million in 2022.
• Annual changes were most pronounced in 2024 — Cash & Equivalents surged 2800.92% — and 2026, when it plunged 97.75%.
• Lakefront Biotherapeutics' Cash & Equivalents stood at $518.4 million in 2022, then plunged by 65.38% to $179.5 million in 2023, then plunged by 61.75% to $68.6 million in 2024, then surged by 49.0% to $102.3 million in 2025, then dropped by 23.53% to $78.2 million in 2026.
• Business Quant data shows LKFT's Cash & Equivalents at $78.2 million in Q1 2026, $102.3 million in Q4 2025, and $3.6 billion in Q3 2025.